hexamethonium has been researched along with Pneumonia in 2 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
Pneumonia: Infection of the lung often accompanied by inflammation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| RESTREPO, G | 1 |
| BAUER, H | 1 |
| PETERSEN, AG | 1 |
| DODGE, M | 1 |
| HELWIG, FC | 1 |
2 other studies available for hexamethonium and Pneumonia
| Article | Year |
|---|---|
Pneumonitis as a complication of hexamethonium therapy.
Topics: Glomerulonephritis; Hexamethonium; Hexamethonium Compounds; Humans; Hypertension; Pneumonia; Vascula | 1958 |
Pulmonary changes associated with hexamethonium therapy.
Topics: Hexamethonium; Hexamethonium Compounds; Hypertension; Pneumonia | 1959 |